Attractiveness of women's body odors over the menstrual cycle: the role of oral contraceptives and receiver sex

It is a long held assumption that women have concealed ovulation, which means that men do not know when women's menstrual cycles are in their most fertile phase. Recent empirical results have provided evidence that ovulation may not be totally concealed from pair-bonded males, but the generality and the mechanisms of the finding demand further study. To examine the possible adaptive value of the phenomenon, it is necessary to study whether the ability to detect ovulation is confined to males. We studied these questions in an experiment in which male and female raters rated the sexual attractiveness and intensity of T-shirts' odors worn by 42 women using oral contraceptives (pill users) and by 39 women without oral contraceptives (nonusers). Males rated the sexual attractiveness of nonusers highest at midcycle. However, female raters showed only a nonsignificant trend for this relationship. Neither sex rated attractiveness of the odors of pill users according to their menstrual cycle. The results indicate that men can use olfactory cues to distinguish between ovulating and nonovulating women. Furthermore, the contrasting results between pill users and nonusers may indicate that oral contraceptives demolish the cyclic attractiveness of odors. Together, these findings give more basis for the study of the role of odors in human sexual behavior. Copyright 2004.body odor; concealed ovulation; Homo sapiens; human; oral contraceptives; reproductive status; sexual selection

Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus

A significant proportion of familial breast cancers cannot be explained by mutations in the BRCA1 or BRCA2 genes. We applied a strategy to identify predisposition loci for breast cancer by using mathematical models to identify early somatic genetic deletions in tumor tissues followed by targeted linkage analysis. Comparative genomic hybridization was used to study 61 breast tumors from 37 breast cancer families with no identified BRCA1 or BRCA2 mutations. Branching and phylogenetic tree models predicted that loss of 13q was one of the earliest genetic events in hereditary cancers. In a Swedish family with five breast cancer cases, all analyzed tumors showed distinct 13q deletions, with the minimal region of loss at 13q21-q22. Genotyping revealed segregation of a shared 13q21 germ-line haplotype in the family. Targeted linkage analysis was carried out in a set of 77 Finnish, Icelandic, and Swedish breast cancer families with no detected BRCA1 and BRCA2 mutations. A maximum parametric two-point logarithm of odds score of 2.76 was obtained for a marker at 13q21 (D13S1308, θ = 0.10). The multipoint logarithm of odds score under heterogeneity was 3.46. The results were further evaluated by simulation to assess the probability of obtaining significant evidence in favor of linkage by chance as well as to take into account the possible influence of the BRCA2 locus, located at a recombination fraction of 0.25 from the new locus. The simulation substantiated the evidence of linkage at D13S1308 (P < 0.0017). The results warrant studies of this putative breast cancer predisposition locus in other populations